Management of Upper Tract Urothelial Carcinoma

被引:21
|
作者
Shvero, Asaf [1 ,2 ,3 ]
Hubosky, Scott G. [1 ]
机构
[1] Thomas Jefferson Univ, Thomas Jefferson Univ Hosp, Sidney Kimmel Med Coll, Dept Urol, 1025 Walnut St,Suite 1100, Philadelphia, PA 19107 USA
[2] Sheba Med Ctr, Dept Urol, Ramat Gan, Israel
[3] Tel Aviv Univ, Tel Aviv, Israel
关键词
Upper tract urothelial carcinoma; Ureteroscopy; Nephron-sparing surgery; Laser ablation; Nephroureterectomy; Topical chemotherapy; Systemic chemotherapy; UPPER URINARY-TRACT; CISPLATIN-INELIGIBLE PATIENTS; BLADDER-CANCER; RADICAL NEPHROURETERECTOMY; ONCOLOGIC OUTCOMES; LYNCH SYNDROME; NEOADJUVANT CHEMOTHERAPY; DIAGNOSTIC URETEROSCOPY; SINGLE-ARM; MULTICENTER;
D O I
10.1007/s11912-021-01179-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review We review the epidemiology, risk factors, diagnosis, and treatment of upper tract urothelial carcinoma (UTUC), with a distinction between the different risk groups. Recent Findings Endoscopic treatment with laser ablation of tumors has an evolving role in treating low-grade UTUC including select large and multifocal tumors, along with complementary topical chemotherapeutic treatment that can reach difficult intrarenal locations. Template lymphadenectomy is recommended in patients undergoing nephroureterectomy. A recent randomized control trial showed benefit of adjuvant chemotherapy after radical nephroureterectomy for locally advanced disease. Advances in immunologic therapy have shown promise in treating metastatic UTUC, and immunologic-based therapies have been incorporated into treatment regimens. Notable progress has been made in both the surgical and medical treatment arms for UTUC, thus extending the reach of nephron-sparing therapy for those with localized disease and increasing overall survival for those with locally advanced disease.
引用
收藏
页码:611 / 619
页数:9
相关论文
共 50 条
  • [1] Management of Upper Tract Urothelial Carcinoma
    Asaf Shvero
    Scott G. Hubosky
    Current Oncology Reports, 2022, 24 : 611 - 619
  • [2] Advancements in the clinical management of upper tract urothelial carcinoma
    Taylor, Jacob
    Meng, Xiaosong
    Ghandour, Rashed
    Margulis, Vitaly
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (12) : 1051 - 1060
  • [3] Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives
    Leow, Jeffrey J.
    Liu, Zhenbang
    Tan, Teck Wei
    Lee, Yee Mun
    Yeo, Eu Kiang
    Chong, Yew-Lam
    ONCOTARGETS AND THERAPY, 2020, 13 : 1 - 14
  • [4] Diagnosis and Management of Upper Tract Urothelial Carcinoma
    Lucca, Ilaria
    Leow, Jeffrey J.
    Shariat, Shahrokh F.
    Chang, Steven L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (02) : 271 - +
  • [5] Upper urinary tract urothelial cell carcinoma
    Gross, A. J.
    Netsch, C.
    Stolzenburg, J. -U.
    Becker, B.
    UROLOGE, 2020, 59 (10): : 1265 - 1274
  • [6] Diagnosis and management of upper tract urothelial carcinoma
    Krabbe, L. -M.
    Bagrodia, A.
    Westerman, M. E.
    Margulis, V.
    MINERVA UROLOGICA E NEFROLOGICA, 2014, 66 (01) : 37 - 48
  • [7] Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need
    Azizi, Mounsif
    Cheriyan, Salim K.
    Peyton, Charles C.
    Foerster, Beat
    Shariat, Shahrokh F.
    Spiess, Philippe E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (05)
  • [8] Management of upper urinary tract urothelial carcinoma
    Sun, Maxine
    Abdo, Al'a
    Abdollah, Firas
    Schmitges, Jan
    Thuret, Rodolphe
    Jeldres, Claudio
    Shariat, Shahrokh F.
    Perrotte, Paul
    Karakiewicz, Pierre I.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (12) : 1955 - 1965
  • [9] Optimizing management of upper tract urothelial carcinoma
    Campbell, Matthew T.
    Shah, Amishi Y.
    Matin, Surena F.
    Siefker-Radtke, Arlene O.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (07) : 492 - 498
  • [10] Therapeutic strategies for upper tract urothelial carcinoma
    Freifeld, Yuval
    Krabbe, Laura-Maria
    Clinton, Timothy N.
    Woldu, Solomon L.
    Margulis, Vitaly
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (08) : 765 - 774